Gynecologic oncology
The sponsor’s research activity centers on cervical cancer and endometrial cancer, with a clear focus on disease settings that remain difficult to treat in the gynecologic oncology field.
- Cervical cancer
- Endometrial cancer
- High-risk locally advanced disease
Its funded studies address both newly diagnosed and more advanced clinical presentations within women’s cancers.
Immune checkpoint therapy
Several trials examine immunotherapy approaches in solid tumors, especially the use of PD-1 and PD-L1 pathway inhibition in gynecologic malignancies.
- Dostarlimab
- Atezolizumab
- Immune-based treatment strategies
These efforts reflect a strong interest in immune-mediated control of tumor growth across cervix and endometrium indications.
Biomarker-defined cancer populations
The sponsor supports research in MMRd and MSI-H disease, highlighting an interest in molecularly selected patient groups within endometrial cancer.
- MMRd tumors
- MSI-H tumors
- Precision oncology
This area links tumor biology with treatment selection in stage II-III endometrial cancer.
Advanced and recurrent cervical cancer
Another major area of interest is metastatic, persistent, and recurrent carcinoma of the cervix, including patients requiring systemic therapy after prior treatment.
- Metastatic cervical cancer
- Persistent cervical cancer
- Recurrent cervical cancer
Studies in this domain focus on treatment options for disease that has progressed beyond initial local management.
Multimodal treatment in locally advanced disease
The sponsor is also involved in research combining chemotherapy, radiation therapy, bevacizumab, and maintenance immunotherapy for high-risk locally advanced cervical cancer.
- Concurrent chemoradiation
- Maintenance therapy
- Combination systemic treatment
This area reflects a therapeutic emphasis on integrating local and systemic approaches in aggressive cervical disease.
